Corvus Pharmaceuticals Inc (CRVS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $897.52M
Last updated: Nov 17, 2026 at 11:05 AM ET
Corvus Pharmaceuticals Inc (CRVS) Competitors
The companies most similar to Corvus Pharmaceuticals are Oric Pharmaceuticals (ORIC), Vor Biopharma (VOR) and Nuvectis Pharma (NVCT). By market cap, Corvus Pharmaceuticals ranks 7th of the 13 companies on this page; Vir Biotechnology (VIR) is the largest at $1.71B.
Peer Comparison
CRVS's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals (CRVS) | $897.52M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Oric Pharmaceuticals Inc (ORIC) | $814.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Vor Biopharma Inc (VOR) | $1.19B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Kura Oncology Inc (KURA) | $713.90M | N/A | 8.0x | 0.0% | -1125.3% | 10.1% | 0.00% |
| Innoviva Inc (INVA) | $1.35B | 5.3x | 3.0x | 44.1% | 10.8% | -1.6% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| CureVac NV (CVAC) | $1.05B | N/A | 1.8x | 182.1% | N/A | -89.0% | 0.00% |
| DBV Technologies (DBVT) | $692.19M | N/A | N/A | 0.0% | -130.3% | -42.9% | 0.00% |
| Tyra Biosciences Inc (TYRA) | $1.38B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| Peer median | $966.74M | 50.2x | 6.0x | 0.0% | -53.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Corvus Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Oric Pharmaceuticals Inc (ORIC) | ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. | ORIC competitors |
| Vor Biopharma Inc (VOR) | Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. | VOR competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Kura Oncology Inc (KURA) | Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. | KURA competitors |
| Innoviva Inc (INVA) | Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California. | INVA competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| CureVac NV (CVAC) | CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). | |
| DBV Technologies (DBVT) | DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. | DBVT competitors |
| Tyra Biosciences Inc (TYRA) | Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes... | TYRA competitors |
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
Frequently Asked Questions About CRVS
Who are Corvus Pharmaceuticals' main competitors?
The companies most similar to Corvus Pharmaceuticals include Oric Pharmaceuticals (ORIC), Vor Biopharma (VOR), Nuvectis Pharma (NVCT), Kura Oncology (KURA) and Innoviva (INVA), listed from the closest match.
Who is Corvus Pharmaceuticals' biggest competitor?
Vir Biotechnology (VIR) is the largest of the similar companies at $1.71B; Oric Pharmaceuticals (ORIC) is the closest match by business profile, size, sector and industry.
How does CRVS stock compare with its competitors?
CRVS' net margin is 0.0% against a peer median of 0.0%.
Which of Corvus Pharmaceuticals' competitors pays a higher dividend?
Corvus Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Corvus Pharmaceuticals bigger than its competitors?
No. Corvus Pharmaceuticals is 7th by market cap among the 13 companies on this page; the largest is Vir Biotechnology (VIR) at $1.71B.
CRVS pages: Overview, Earnings, Forecast, Financials, Competitors